Eascra Biotech
PrivateLast Round
Grant
Mar 25, 2026
Total Funding Raised
$2.31M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Eascra Biotech is a biotechnology company that provides a nanomedicine platform for precision therapeutic delivery to hard-to-penetrate tissues like articular cartilage, kidneys, and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Space Technology
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eascra Biotech Comparables
Compare Eascra Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vesicle Therapeutics | 87% | |
| Vesigen Therapeutics | 86% | |
| EV Therapeutics | 82% |
Eascra Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 25, 2026 | ||||
| Accelerator | Jul 24, 2025 | ||||
| Grant | May 19, 2025 | ||||
| Grant | Apr 21, 2025 | ||||
| Grant | Mar 7, 2025 | ||||
Grant | Aug 2, 2024 |
Eascra Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MassVentures | Grant |
| United States Air Force | Grant |
| MassChallenge Israel | Grant |
| TechConnect | Grant |
| Massachusetts Biomedical Initiatives | Accelerator |
| AFVentures | Grant |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 102% MoM, reaching 1.6K.
- Jun 28, 2026
Grew 60% QoQ from 5 to 8 employees.
Recent news
Latest coverage and updates
- receives_financingAug 31, 2026
Eascra Biotech recently receives more than $8M through NSF and AFWERX SBIR grants, awards and commercial-sponsored research from organizations including NASA and MassVentures.
- partners_withAug 27, 2026
Eascra Biotech works with ISS National Lab and other space organizations to accelerate its go-to-market strategy, after testing its product in microgravity in 2025.
- hiresAug 27, 2026
Eascra Biotech appoints Dr. Andrew Goodearl as Chief Scientific Officer to advance its commercialization strategy and accelerate product development in Massachusetts on Aug 27th '26.
Eascra Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Eascra Biotech's valuation, stock price, and market status.
Is Eascra Biotech a public or private company?
Eascra Biotech is a private company.
What is the current stock price of Eascra Biotech?
Eascra Biotech is a private company, so its shares have no public market price. Caplight tracks Eascra Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eascra Biotech worth (valuation)?
Valuation information for Eascra Biotech is not publicly available.
Can I buy Eascra Biotech stock?
Eascra Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eascra Biotech's last funding round?
Eascra Biotech's most recent funding round was Grant on March 25, 2026.
Who are the main investors in Eascra Biotech?
Key investors in Eascra Biotech include MassVentures, MassChallenge Israel.
Will Eascra Biotech IPO soon?
No public IPO plans have been announced for Eascra Biotech.
How can I track Eascra Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Eascra Biotech's shares on secondary markets.